References
- Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009;40:1754–61
- Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674–81
- Heston WD. Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. Urology 1997;49:104–12
- Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749–53
- Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26:5310–24
- Tsukamoto T, Wozniak KM, Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007;12:767–76
- Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005;4:1015–26
- Wu LY, Anderson MO, Toriyabe Y, et al. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 2007;15:7434–43
- Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 2008;47:12658–60
- Nedrow-Byers JR, Moore AL, Ganguly T, et al. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate 2012;73:355–62
- Nedrow-Byers JR, Jabbes M, Jewett C, et al. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate 2011;72:904–12
- Liu T, Wu LY, Hopkins MR, et al. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 2010;20:7124–6
- Liu T, Nedrow-Byers JR, Hopkins MR, et al. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorg Med Chem Lett 2012;22:3931–4
- Wu, LY, Liu, T, Hopkins, MR, et al. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate 2012;72:1532–41
- Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 2006;49:251–5
- Maun HR, Wen X, Lingel A, et al. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J Biol Chem 2010;285:26570–80
- Paek SH, Cho IH, Kim DH, et al. Label-free, needle-type biosensor for continuous glucose monitoring based on competitive binding. Biosens Bioelectron 2012;40:38–44